The Fc component of IGg4 – the stalk of the antibody – prevents the cancer functionality of IGg1 from killing cancer cells
“Conclusion There appears to be a previously unrecognized immune evasion mechanism with IgG4 playing an essential role in cancer microenvironment with implications in cancer diagnosis and immunotherapy.”
Dr. Raszek discusses the paper in a 33-minute video here:
Turbo cancers part 2: the role of IgG4! (update #139) (youtube.com)
“This is the second installment of a series dedicated to the molecular biology of the highly unusual and deadly turbo cancers (called hyperprogressive disease in medicine).
In this episode, we look at how IgG4 can play a role by itself in cancer progression via its Fc stalk and its ability to interact with either other cancer-fighting IgG1 (and preventing their protective role) or by blocking immune cells from performing their protective roles.
What we cover:
*Cancer patients showed 11% IgG4 levels of total IgG antibodies in comparison to 3% in healthy subjects
*IgG4 levels positively correlated with the stage of cancer
*IgG4 level/total amount of IgG can be prognostic of cancer recurrence (past studies)
*IgG4 is about 4X higher in cancer tissue than adjacent tissue
*IgG4 can bind to anti-cancer IgG1 antibodies and inhibit their function
*IgG4 does not have to target the cancer itself at all to help cancer growth
*Co-injection of IgG4 of any type with cancer cells into mice always increases the tumor size/weight
*It is the Fc stalk of IgG4 antibody that is responsible for its pro-tumor effects”
Onwards!!!
Please subscribe ten dollars a month or annually for 100 bucks. You can also donate via Ko-fi – any amount from three dollars upwards. Ko-fi donations here: https://ko-fi.com/peterhalligan
Given the turbo cancers are obviously related to cv injections, wouldn't it make sense to inject the mice with the various known and suspected ingredients of the vaccines, one by one, and identify which of the toxins lead to proliferation of IgG4, rather than injecting them directly with cancer cells?
h/t Jayne dOE:
"Friend or Foe Cancer" paper author's recent work as well - https://www.sciencedirect.com/science/article/abs/pii/S0141813024022323
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
""future clinical trials for cancers or infectious diseases should not use mRNA vaccines with a 100 % m1Ψ modification, but rather ones with the lower percentage of m1Ψ modification to avoid immune suppression."
mORE HUMAN EXPERIMENTATION NEEDED TO DETERMINE THE OPTIMAL LEVEL OF m1Ψ